Greenwich LifeSciences, Inc. (GLSI): Total Liabilities
$5.82M
As of 2025-12-31
$5.76M
As of 2026-06-30
+180.9%
3-year compound annual growth
+41.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.82M | n/a | 2026-06-01, Balance as of period end |
| 2025-09-30 | $2.02M | n/a | 2026-06-01, Balance as of period end |
| 2025-06-30 | $2.52M | n/a | 2026-06-01, Balance as of period end |
| 2025-03-31 | $2.55M | n/a | 2026-06-01, Balance as of period end |
| 2024-12-31 | $3.19M | +981.9% | 2026-06-01, Balance as of period end |
| 2023-12-31 | $294.4K | +12.0% | 2025-04-15, Balance as of period end |
| 2022-12-31 | $262.9K | -31.7% | 2024-04-15, Balance as of period end |
| 2021-12-31 | $385.2K | -63.2% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $1.05M | -24.1% | 2022-03-21, Balance as of period end |
| 2019-12-31 | $1.38M | n/a | 2021-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | 2025-12-31 | $5.82M | n/a |
| GeoVax Labs, Inc. (GOVX) | 2025-12-31 | $2.52M | -19.0% |
| Vyome Holdings, Inc (HIND) | 2025-12-31 | $2.74M | -52.6% |
| Kairos Pharma, Ltd. (KAPA) | 2024-12-31 | $992.0K | -67.4% |
| Ernexa Therapeutics Inc. (ERNA) | 2025-12-31 | $3.43M | -3.8% |
| Adial Pharmaceuticals, Inc. (ADIL) | 2025-12-31 | $1.40M | +43.1% |
| CDT Equity Inc. (CDT) | 2025-12-31 | $12.82M | +16.7% |
| OS Therapies Inc (OSTX) | 2025-12-31 | $11.86M | +151.0% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $7.40M | +264.3% |
Compare GLSI, GOVX, HIND, KAPA side by side · Screen every company in Pharmaceutical Preparations ↗